Trials / Conditions / Metastatic Renal Cell Carcinoma (mRCC)

Metastatic Renal Cell Carcinoma (mRCC)

11 registered clinical trials studyying Metastatic Renal Cell Carcinoma (mRCC) — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advan NCT07188896	Brian Rini	Phase 2
Recruiting	Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415	Pfizer	Phase 1 / Phase 2
Not Yet Recruiting	Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC NCT07233668	Seoul National University Hospital	N/A
Recruiting	Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer NCT06601296	University of Texas Southwestern Medical Center	Phase 2
Recruiting	PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk NCT07175480	Jinling Hospital, China	Phase 2
Recruiting	International Multicentric Study ARON-1 NCT05287464	Hospital of Macerata	—
Completed	A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Pati NCT04115189	Pfizer	—
Completed	Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Li NCT04175262	Pfizer	—
Completed	Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1s NCT02184416	Pfizer	—
Completed	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With NCT01514448	Novartis Pharmaceuticals	Phase 4
Completed	A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatmen NCT01390519	Novartis Pharmaceuticals	—